Eplontersen fda approval

WAINUA (eplontersen) Approved in US for Adult Polyneuropathy in Hereditary Transthyretin Amyloidosis In the United States, the FDA has

The FDA on Thursday approved AstraZeneca's and Ionis Pharmaceuticals' antisense therapeutic eplontersen, which will now carry the brand name

FDA Approves WAINUA (Eplontersen) for Treatment of Hereditary ATTR Amyloidosis Polyneuropathy (ATTRv-PN). 252

Onpattro (patisiran) was both the first siRNA drug to ever receive FDA approval and the first The news that regulatory approval will be sought for eplontersen

The FDA has approved vutrisiran (Amvuttra), patisiran (Onpattro), inotersen (Tegsedi), and eplontersen (Wainua) for treatment of polyneuropathy

Wainua will enter the US market in January 2024 after positive Phase III data landed it an FDA approval for ATTRv-PN (eplontersen) for a

The FDA has approved eplontersen (Wainua) to treat hereditary transthyretin-mediated amyloidosis (hATTR)-associated polyneuropathy.

The U.S. Food and Drug Administration (FDA) has granted approval to Wainua (eplontersen) for the treatment of the polyneuropathy of

Eplontersen marks a groundbreaking advancement as the first self-administered, FDA-approved drug for the management of hATTR-PN in adults. Eplontersen is a ligand-conjugated antisense oligonucleotide directed toward TTR protein.